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Summary
Nonsyndromic cleft lip with or without cleft palate (CL/
P) and nonsyndromic cleft palate only (CPO) are com-
mon congenital anomalies with significant medical, psy-
chological, social, and economic ramifications. BothCL/
P and CPO are examples of complex genetic traits. There
exists sufficient evidence to hypothesize that disease loci
for CL/P and CPO can be identified by a candidate-gene
linkage-disequilibrium (LD) strategy. Candidate genes
for clefting, including TGFA, BCL3, DLX2, MSX1, and
TGFB3, were screened for LD with either CL/P or CPO
in a predominantly Caucasian population, with both
case-control– and nuclear-family–based approaches.
Previously reported LD for TGFA with both CL/P and
CPO could not be confirmed, except in CL/P patients
with a positive family history. Also, in contrast to pre-
vious studies, no LD was found between BCL3 and ei-
ther CL/P or CPO. Significant LD was found between
CL/P and both MSX1 and TGFB3 and between CPO
and MSX1, suggesting that these genes are involved in
the pathogenesis of clefting. In addition, a mutation
search in the genes DLX2, MSX1, and TGFB3 was per-
formed in 69 CPO patients and in a subset of the CL/
P patients. No common mutations were found in the
coding regions of these genes; however, several rare var-
iants of MSX1 and TGFB3 were found that may alter
the latters’ normal function. These results form the basis
for future research, including (a) mutation searches in
theMSX1 and TGFB3 genes in Caucasian CL/P patients
and (b) extension of the search for MSX1 mutations in
CPO patients to the noncoding regions.
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Introduction
Both nonsyndromic cleft lip with or without cleft palate
(CL/P [MIM 119530]) and cleft palate only (CPO [MIM
119540]) are common birth defects with characteristics
of genetically complex traits. Segregation analysis and
epidemiological studies have shown that 25%–35% of
CL/P and 10%–20% of CPO patients have a family
history of clefting and that simple Mendelian-inheritance
models are insufficient to explain the mode of inheri-
tance in families segregating clefting (Fogh-Andersen
1942; Jones 1993; reviewed by Wyszynski et al. 1996).
In addition, CL/P and CPO are heterogeneous traits with
an estimated 2–20 genes interacting multiplicatively to
cause clefts, including a possible major gene that may
account for 10%–50% of the incidence of these birth
defects (Mitchell and Risch 1992; Fitzpatrick and Farrall
1993; Christensen and Mitchell 1996).
To identify gene(s) involved in CL/P and CPO, inves-
tigators have used both association and linkage strate-
gies to evaluate candidate genes, focusing primarily on
CL/P. Associations with TGFA, RARA, D4S191, and
BCL3 have been found for CL/P (reviewed by Murray
1995; Wyszynski et al. 1996), and linkage with BCL3
and 6p has been found for CL/P (Scapoli et al. 1997),
whereas an association with TGFA has been found for
CPO (Shiang et al. 1993; Hwang et al. 1995). Most of
the association studies have employed case-control study
designs, which are potentially susceptible to population-
structure problems. However, family-based study de-
signs that control for the effect of stratification have been
developed and can be applied to clefting (Spielman et
al. 1993; Thomson 1995). Current technology precludes
a genome scan for associations with clefting, thus ne-
cessitating the careful selection of candidate genes to
study. The advent of gene targeting has led to the iden-
tification of several additional candidate cleft genes, in-
cluding DLX2 (Qiu et al. 1995, 1997), MSX1 (Satokata
and Maas 1994), and TGFB3 (Kaartinen et al. 1995;
Proetzel et al. 1995).
The purpose of this research was to test the hypothesis
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that TGFA, BCL3, DLX2, MSX1, and TGFB3 are in-
volved in the etiology of CL/P or CPO. This was tested
by determining, through the use of both case-control–
and nuclear-family–based approaches, whether these
genes were in linkage disequilibrium (LD) with either
form of clefting. Further testing of the hypotheses was
performed by screening CPO patients for mutations in
the DLX2, MSX1, and TGFB3 genes.
Subjects and Methods
Populations
An Iowa population that is 95% Caucasian was avail-
able to ascertain, by two different mechanisms, cleft lip
and cleft palate patients as well as controls. This study
has University of Iowa institutional-review-board ap-
proval, and informed consent was obtained from all sub-
jects. Initially, a sample of unrelated patients with CL/
P ( ) and CPO ( ), as well as unmatchedN  110 N  16
controls born during 1956–87, were ascertained by
means of a clinic-based mechanism (Ardinger et al.
1989). The second mechanism was a population-based
case-control study within the University of Iowa Cran-
iofacial Anomalies Research Center (CARC) (Romitti et
al. 1998). Patients with CL/P ( ) and CPON  133
( ), as well as their parents, were ascertainedN  61
through the Iowa Birth Defects Registry, and control
children were selected from birth tapes. For simplifica-
tion, the first mechanism of ascertainment has been des-
ignated “Ardinger,” and the second mechanism has been
designated “CARC.” All patients having a known syn-
drome or other major or multiple minor defects, as de-
termined by a clinical exam or a record review (by
J.C.M. and S.D.-H. [Ardinger et al. 1989]), were ex-
cluded during data analysis.
LD Analysis
The cleft patients were separated into two groups, CL/
P and CPO, for LD analysis. The case-control compar-
isons in this study used only CARC controls and com-
pared them with all of the CL/P or CPO patients from
both mechanisms of ascertainment. The family-based
control analyses were performed only on CARC sub-
jects, since the parental samples were not collected for
the first mechanism. The case-control analysis utilizes a
larger data set, because not all families were fully as-
certained. Two family-based approaches were used, in-
cluding (1) the affected-family–based control (AFBAC)
method, which uses parental and proband genotypes to
compare all the transmitted alleles with the untransmit-
ted alleles (Thomson 1995), and (2) the transmission/
disequilibrium test (TDT) (Spielman et al. 1993). AF-
BAC has greater power to detect association than TDT
has when no population structure exists, which can be
proved by Hardy-Weinberg equilibrium (HWE) for two
generations (Spielman and Ewens 1996). In the presence
of population structure, TDT is more powerful, since
AFBAC loses power by a larger denominator. However,
the size of this underestimation is difficult to predict and
may be minimal. Therefore, AFBAC is a more conser-
vative test. In addition, TDT detects linkage in the pres-
ence of association and is valid if population structure
exists. Both the case-control and the AFBAC data were
analyzed by means of contingency tables, which2 # n
were evaluated by either the Pearson x2 test; Fisher’s
exact test, when any of the cells had an expected fre-
quency of X5; or the likelihood-ratio test (LRT) (Ter-
williger 1995). Alleles or haplotypes were pooled to-
gether when the overall observed frequency for either
the sum of the patient and control alleles or the sum of
the transmitted and untransmitted alleles was X5%
(Long et al. 1995). The TDT data for multiallelic mark-
ers were analyzed by the recently proposed TDT statistic
using a correction (where k is the number ofk 1/k
alleles), which takes into account the possibility that
more than one allele is positively or negatively associated
(Spielman and Ewens 1996). Data from families with
one parent missing were also used in the TDT analyses
(Curtis and Sham 1995; Spielman and Ewens 1996).
Bonferroni correction for 95 comparisons would yield
a strict . Haplotypes were determined bya  .00054
GENEHUNTER and were confirmed visually (Kruglyak
et al. 1996).
DNA Extraction and Genotyping
DNA was extracted from isolated nuclei of leukocytes,
blood spots (Lidral et al. 1997), or buccal mucosa cells
(Richards et al. 1993). PCRs were performed in 10-ml
volumes containing 2–4 ng DNA/ml; 200 mM each of
dATP, dCTP, dGTP, and dTTP; 1.5 mM MgCl2; 10 mM
Tris/HCl pH 8.3; 50 mM KCl; 0.001% (w/v) gelatin;
0.25–1.0 mM of each primer; and 0.01–0.02 unit Taq
polymerase/ml. Standard thermocycling was as follows:
94C for 20–45 s, the primer-specific annealing temper-
ature for 20–45 s, and 72C for 30 s. Dimethyl sulfoxide
(DMSO), 5%–10% (v/v), was added to aid in amplifi-
cation of GC-rich regions, and the amount of Taq poly-
merase was doubled to compensate for the inhibition of
DMSO on Taq polymerase.
Markers used include TGFA TaqI (Basart et al. 1994),
BCL3 CA (St. George-Hyslop et al. 1992), MSX1 CA
(Padanilam et al. 1992), and TGFB3 CA (Lidral et al.
1997). An additional marker for TGFA, GGAA4D07
(D4S433), was mapped to the YAC 697h1 containing
the TGFA gene. SSCPs for DLX2, MSX1, and TGFB3
were discovered during the mutation screening of the
CPO patients. These polymorphisms include DLX2
X2.2; MSX1 X1.1, MSX1 X1.3, MSX1 X2.1, and
Lidral et al.: MSX1 and TGFB3 Associated with Clefting 559
MSX1 X2.4; and TGFB3 X5.1 (see Website Lidral et
al., AJHG [1998], table 12 and appendixes 2–8; data
also are available, on request, from the authors). In ad-
dition, a hexanucleotide repeat for TGFB3 5′ UTR.1 was
identified by the Cooperative Human Linkage Center
primer server (Murray et al. 1994). This TGFB3 repeat
polymorphism was simultaneously identified by C. Van
Broeckhoven (Genome Database accession number
386112), who reported similar allele frequencies.
Subjects were genotyped by means of SSCP, mutation-
detection enhancement (MDE), and PAGE techniques.
Gels were loaded with either internal controls consisting
of samples with known genotypes or a DNA sequencing
ladder and were silver stained (Lidral et al. 1997).
Screening for Genetic Variations and Mutations
The genes MSX1 and TGFB3 were screened for mu-
tations in 24 CL/P and 69 CPO patients, including 2
patients with submucous clefts and 1 patient with a bifid
uvula, by means of SSCA (Orita et al. 1989) and MDE
gels (Soto and Sukumar 1992). A variable number of
CPO patients, ranging, for different primer pairs, from
22 to 69, were screened similarly, for mutations in ∼50%
of the DLX2 coding region. Overlapping primer pairs
(see Website Lidral et al., AJHG [1998], appendix 1)
were developed to amplify the coding regions, including
the splice sites and potential splicing branch sites (Ma-
quat 1996), of DLX2 (J.L.R. Rubenstein, unpublished
data), MSX1 (Hewitt et al. 1991), and TGFB3 (Derynck
et al. 1988; ten Dijke et al. 1988; Lafyatis et al. 1990).
Sequencing
Sequencing was performed in both directions on DNA
samples from two to three individuals, when possible.
Templates included either (1) PCR products purified by
agarose gels or Qiaquick PCR columns (Qiagen) or (2)
asymmetric PCR products generated by use of a primer
ratio of 100:1 (20 mM:0.2 mM) and were purified by
Qiaquick columns. If necessary, the PCR fragments were
cloned into pKRX, and 10–20 positive clones were
pooled for sequencing (Pruessner et al. 1995). Templates
were sequenced by incorporation of either 33P or dye
terminators into cycle-sequencing products, by means of
AmpliCycle kits (Perkin-Elmer).
Results
Population Structure
Two anonymous markers chosen at random were
evaluated to determine whether there were inherent dif-
ferences between the patient and control groups. Neither
GATA-49C05 nor GATA-51F02 showed any differences
between the groups or any evidence of transmission dis-
tortion (see Website Lidral et al., AJHG [1998], appen-
dixes 13 and 14). In addition, HWE exists for the con-
trol, CL/P, and CPO groups, for all the markers (data
not shown). However, it was not possible to prove HWE
for two generations in these groups, which would in-
dicate that no population structure exists. TDT is more
powerful with population structure, whereas AFBAC is
more powerful when no population structure exists
(Spielman and Ewens 1996). Therefore, both tests were
used—AFBAC because there was no evidence to indicate
that structure exists and TDT to improve power if the
opposite proved to be the case. Also, AFBAC would
underestimate association rather than lead to false-pos-
itive findings.
TGFA, BCL3, and DLX2
LD between CL/P or CPO and either the TGFA TaqI
marker or the GGAA4D07 marker was not detected, by
either case-control or family-based approaches (table 1;
see also Website Lidral et al., AJHG [1998], appendixes
9 and 10). Also, haplotypes of the TaqI and GGAA4D07
polymorphisms did not show evidence of transmission
disequilibrium in either the CL/P families or the CPO
nuclear families (data not shown). In addition, no evi-
dence of LD between BCL3 or DLX2 and CL/P or CPO
was found by family-based analyses (see Website Lidral
et al., AJHG [1998], appendixes 9 and 10). No muta-
tions were identified during a screening of the DLX2
coding regions, amplified by the primers X1.3, X1.4,
X2.1, X2.2, X3.1, and X3.3, in CPO patients.
MSX1 Mutation Screen and LD
Four polymorphic variants of MSX1 were identified
during the mutation screen of the CPO patients. These,
along with MSX1 CA variant, were genotyped in the
patient and control groups. LD was observed between
the CA marker and CPO and between the X1.3 marker
and both the CPO and the CL/P groups (table 1).
To address the possibility of population stratification,
the data were analyzed by use of nuclear families. Seg-
regation distortion in the control group was not evident
for any of the markers (A.C. Lidral, unpublished data).
TDT and AFBAC analyses did not show evidence for
LD between CL/P and any MSX1 marker (tables 2 and
3). Only the CA marker showed LD with CPO
(table 3).
Haplotyping was performed on all the markers, to
determine whether LD existed for any haplotype(s). Nei-
ther TDT nor AFBAC found LD with any haplotype
consisting of markers CA, X1.1, X1.3, X2.1, and X2.4
(table 4). However, a case-control comparison of hap-
lotypes for all five markers showed nearly significant LD
with CL/P and CPO (table 5).
A mutation screen of the MSX1 coding region in 69
Iowa CPO patients and 24 CL/P patients revealed nu-
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Table 1
Individual Markers: Case-Control LD
MARKER AND
POPULATION
NO. OF CHROMOSOMES OF ALLELE TYPEa
P1 2 3 4 5 6 7 8 9 10 11
TGFA GGAA4D07:
Control 1* 26 8* 37 114 114 65 19† 18† 12* 3*
CL/P 3‡ 25 18‡ 43 103 97 53 18§ 11§ 6‡ 0‡ .84
CPO 0k 8 2k 6 35 32 12 9# 4# 4k 1k .66
TGFA TaqI:
Control 449 53
CL/P 327 37 .85
CPO 109 15 .62
MSX1 CA:
Control 64 139 37 310
CL/P 37 100 19 240 .35
CPO 12 28 1 79 .027b
MSX1 X1.1:
Control 20 250 60 0 0 0
CL/P 27 275 67 0 1 0 .80
CPO 7 76 19 0 0 0 .95
MSX1 X1.3:
Control 5 313
CL/P 22 372 .005
CPO 8 114 .0057
MSX X2.1:
Control 3** 303 94**
CL/P 1†† 292 81†† .44
CPO 0 88 24 .53
MSX1 X2.4:
Control 66 182
CL/P 90 268 .68
CPO 22 78 .37
TGFB3 CA:
Control 303 161 22
CL/P 201 127 22 .27
CPO 63 38 5 .85
TGFB3 5′ UTR.1:
Control 453 29
CL/P 337 17 .45
CPO 98 8 .56
TGFB3 X5.1:
Control 122 8
CL/P 156 8 .63
CPO 66 4 1.00b
a Superscript symbols denote alleles that were pooled.
b Calculated by the exact test.
merous variants (table 6; see also Website Lidral et al.,
AJHG [1998], appendices 3–6). These were either pol-
ymorphisms or rare variants found in controls, patients,
or their parents.
TGFB3 Mutation Screening and LD
The mutation screen of the TGFB3 coding region, ex-
cluding exon 4, and of the promotor/5′ UTR region,
amplified by the primer pair 5′ UTR.1, revealed four
variants in the Iowa CPO subjects. These occurred in
the TGFB3 5′ UTR and in exons 2, 5, and 7 (see Website
Lidral et al., AJHG [1998], appendixes 7, 8, 11, and
12). The TGFB3 5′ UTR.1 and X5.1 variants are poly-
morphisms (table 1), whereas X2.1 and X7.1 are rare
variants (table 6; A.C. Lidral, unpublished data). 5′
UTR.1 is caused by a hexanucleotide repeat within 50
nucleotides from the transcription initiation sites, and
X5.1 is caused by a TrC mutation in intron 4 (table 6).
When a case-control design was used, LD between
any TGFB3 marker and either CL/P or CPO was not
detected (table 1). The TDT analysis showed LD be-
tween CL/P and the TGFB3 X5.1 marker, as well as a
trend toward LD between CL/P and the TGFB3 5′ UTR.1
marker (table 2). The same analyses did not show LD
between CPO and any TGFB3 marker (table 2). There
was significant LD between CL/P and the TGFB3 5′
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Table 2
TDT LD of Individual Markers
GENE, MARKER,
AND ALLELE
CL/P CPO
Transmitted Untransmitted x2 P Transmitted Untransmitted x2 P
MSX1:
CA:
1 13 15 6 5
2 29 31 8 14
3 8 8 0 3
4 36 31 .43 .93 19 9 6.23 .11
X1.1:
1 9 8 5 2
2 26 28 13 13
3 22 21 .10 .95 10 11 .89 .64
X1.3:
1 8 5 .69 .41 3 2 .20 .65
X2.1:
1 1 1 0 0
2 20 26 8 12
3 24 20 .76 .68 12 8 .80 .36
X2.4:
1 31 29 .67 .41 11 13 .17 .68
TGFB3:
CA:
1 30 35 10 11
2 25 24 8 7
3 14 8 1.36 .51 3 3 .08 .80
5′ UTR.1:
1 13 6 2.58 .11 5 4 .11 .75
X5.1:
1 10 3 3.77 .05 1 2 .33 .58
UTR.1–X5.1 haplotype (table 7). However, in the Iowa
population, there was no evidence of LD between any
TGFB3 haplotype and CPO (data not shown).
Since there was an association between the TGFB3 5′
UTR.1–X5.1 haplotype and CL/P, and since there is ev-
idence for maternal transmission of TGFB1 in mice (Let-
terio et al. 1994), the data were analyzed to determine
whether there was a maternal effect for TGFB3. The
TGFB3 5′ UTR.1–X5.1 haplotype frequency in mothers
of CL/P and CPO patients was compared with that in
mothers of controls. No significant difference between
the haplotype frequencies was evident (data not shown).
To evaluate whether there was interaction between
TGFB3 and MSX1, the frequencies of the MSX1 X1.3
alleles in conjunction with the TGFB3 5′ UTR.1–X5.1
haplotypes were compared, between the patients and the
controls. There was no evidence for interaction with the
CPO phenotype; however, there was a trend ( )P  .058
toward such interaction in the CL/P patients (data not
shown). The MSX1 X1.3 allele 1 and the TGFB3
5′ UTR.1–X5.1 haplotype 1-1, which were shown to be
independently associated with CL/P, were found in com-
bination with each other more frequently in the CL/P
chromosomes (7/92) than in the control chromosomes
(1/100).
Discussion
TGFA
When two markers were used, there was no significant
evidence of LD between TGFA and either CL/P or CPO,
in either the case-control– or the nuclear-family–based
approach. The differences between these results and
those of previous studies of the same population are due
to a higher frequency of the rare TaqI C2 allele in the
current control population than in the control popula-
tion used in the previous studies: 9.8% in the present
study, versus 8.5% (Shiang et al. 1993) and 5.1% (Ar-
dinger et al. 1989) in the previous studies. Also, the C2
allele is less common in affected individuals in the pre-
sent study: frequency 10% in CL/P patients, versus
13.5% (Ardinger et al. 1989) and 12.6% in CPO pa-
tients, versus 19.8% (Shiang et al. 1993). The earlier
studies were not population based and relied on con-
venient control samples, including laboratory workers,
placentas, and subjects with other diseases, in contrast
to the current study. Two previous reports, using case-
control comparisons, have shown LD between TGFA
and CPO in Caucasian populations (Shiang et al. 1993;
Hwang et al. 1995), and a third almost reached signif-
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Table 3
AFBAC LD of Individual Markers
GENE, MARKER
AND ALLELE
CL/Pa CPOa
Transmitted Untransmitted x2 P Transmitted Untransmitted x2 P
MSX1:
CA:
1 14 15 7* 9*
2 39 43 11 17
3 7 8 0* 3*
4 98 92 .49 .92 36 25 3.07 .04
X1.1:
1 10 9 4 2
2 102 105 40 38
3 26 23 .28 .87 8 12 1.52 .49b
X1.3:
1 10 7 3 2
2 158 161 .56 .46 65 66 .21 .65
X2.1:
1 1† 1† 0 0
2 109 113 47 51
3 30† 26† .35 .55 13 9 .89 .35
X2.4:
1 40 36 12 15
2 114 118 .28 .60 48 45 .43 .51
TGFB3:
CA:
1 68 73 28 29
2 41 40 11 10
3 13 9 .92 .63 3 3 .065 .97
5′ UTR:
1 155 148 53 52
2 7 14 2.50 .11 5 6 .10 .75
X5.1:
1 99 92 32 33
2 3 10 4.02 .08b 2 1 .35 .55
a Superscript symbols denote alleles that were pooled.
b Calculated by the exact test.
icance (Shaw et al. 1996), whereas another showed no
LD (Stoll et al. 1993). Similarly, LD between TGFA and
CL/P has been found in various populations, but not in
others, by case-control study designs (reviewed by Wy-
szynski et al. 1996). There has been considerable vari-
ation in study designs, markers used, and percentage of
patients with a positive family history, such that direct
comparisons are difficult. Also, there is a wide range in
the TGFA TaqI C2 allele frequency—6.5%–19.8% for
CPO, 4%–16.9% for CL/P, and 4%–14% for con-
trols—suggesting that heterogeneity between the popu-
lations may exist. Other studies using family-based LD
designs have been contradictory (Feng et al. 1994; Maes-
tri et al. 1997; Wyszynski et al. 1997a; Scapoli et al.
1998). A recent metanalysis of all the published reports
showed significant evidence for LD in Caucasian pop-
ulations (Mitchell 1997). This analysis also revealed sig-
nificant heterogeneity between the CL/P samples from
the different studies, but not in the control samples. The
origin of this heterogeneity could not be clearly discerned
from the potential explanatory factors such as popula-
tion stratification, cleft severity, or percentage of patients
with a positive family history of clefting. Population
stratification is unlikely, given that the control popula-
tions have similar frequencies. Also, the severity of clefts
is not significantly different between these studies. One
study that did not find LD with CL/P excluded all pa-
tients with a positive family history for CL/P (Stoll et
al. 1993), suggesting that a family history of clefting
may correlate with the TGFA TaqI rare variant. The
proportion of patients with a positive family history is
lower in the present study’s data set than in previous
studies of this population (Ardinger et al. 1989), which
may explain the current lack of LD. The importance of
a positive family history is demonstrated in the present
study by the significant transmission of the rare allele
( ) to CL/P patients with a positive family his-P  .014
tory (P.A. Romitti and J.C. Murray, unpublished data).
However, two previous studies (Hecht et al. 1991; Vin-
tiner et al. 1992) did not reveal linkage between TGFA
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Table 4
MSX1 CA–X1.1–X1.3–X2.1–X2.4 Haplotype: TDT and AFBAC Analysis
POPULATION
AND HAPLOTYPE
TDT AFBAC
Transmitted Untransmitted x2 P Transmitted Untransmitted x2 P
CLP:
1-2-2-2-2 6 7 5* 8*
1-2-2-3-2 1 0 1† 0†
1-3-2-2-2 0 2 0† 2†
2-2-2-2-2 14 18 18 22
2-2-2-3-2 0 1 0† 1†
2-4-2-2-2 0 1 0† 1†
3-2-1-2-2 1 0 1† 0†
3-2-2-2-2 5 4 4* 3*
3-2-2-3-2 0 2 0† 2†
4-1-2-2-2 0 1 0‡ 1‡
4-1-2-3-1 5 6 5§ 5§
4-2-1-2-2 3 2 4‡ 3‡
4-2-2-1-2 1 0 1‡ 0‡
4-2-2-2-2 18 13 24 23
4-2-2-3-1 1 1 1‡ 1‡
4-2-2-3-2 1 1 0‡ 1‡
4-3-2-2-1 7 4 7§ 0§
4-3-2-2-2 1 0 1‡ 0‡
4-3-2-3-1 6 7 12.97 .74 8 7 5.65 .47b
CPO:
1-2-2-2-2 4 3 2* 3*
1-2-2-3-2 1 0 1† 0†
1-3-2-2-2 1 1 1* 1*
2-2-2-2-2 6 14 6 14
2-2-2-3-2 1 0 1† 0†
3-2-2-2-2 0 2 0† 1†
3-3-2-3-1 0 1 0† 1†
4-1-2-2-1 0 1 0‡ 1‡
4-1-2-3-1 0 1 0‡ 1‡
4-2-1-2-2 2 1 2‡ 1‡
4-2-2-2-2 12 6 13 5
4-2-2-3-2 1 0 1‡ 0‡
4-3-2-2-1 3 2 2‡ 2‡
4-3-2-3-1 4 3 13.00 .45 3 2 7.10 .28b
a Superscript symbols denote alleles that were pooled on the basis of at-risk allele 4 of the CA marker.
b Calculated by the exact test.
and CL/P in small collections of multiplex families,
which underscores the heterogeneity of clefting.
A role for TGFA in clefting is not supported by data
from transgenic mice, regardless of whether the latter
are ectopically expressing or null mutants (Jhappan et
al. 1990; Sandgren et al. 1990; Luetteke et al. 1993;
Mann et al. 1993). Transgenic knockout or dominant-
negative mice mutant for EGFR, the receptor for TGFA,
also have normal craniofacial development (Murillas et
al. 1995; Sibilia and Wagner 1995; Threadgill et al.
1995).
Recently, an additive association of the TGFA TaqI
C2 allele and smoking has been shown, with CPO, in
both a Maryland population (Hwang et al. 1995) and
in an Iowa population (P.A. Romitti and J.C. Murray,
unpublished data), and with both CL/P and CPO, in
California and Mid-Atlantic populations (Shaw et al.
1996; Maestri et al. 1997). In addition, certain TGFA
genotypes and alcohol exposure have been shown to
increase risk for CL/P (P.A. Romitti and J.C. Murray,
unpublished data). These data suggest that TGFA may
modulate susceptibility to environmental exposures.
BCL3 and DLX2
No evidence for LD between BCL3 and either CL/P
or CPO was detected, in contrast to the results reported
in previous studies (Stein et al. 1995; Amos et al. 1996;
Maestri et al. 1997; Wyszynski et al. 1997b). The data
from the present study do not show evidence for LD
between DLX2 and either CL/P or CPO. Furthermore,
no mutations were found in a partial screen of the DLX2
coding region in CPO patients. The phenotype of the
mouse knockout indicates that a similar mutation in
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Table 5
MSX1 CA–X1.1–X1.3–X2.1–X2.4 Haplotype: Case-Control LD
HAPLOTYPE
NO. OF CHROMOSOMESa
Control CL/Pb CPOc
1-2-2-2-2 18* 10 6
1-2-2-3-2 0*,† 1* 1†
1-3-2-2-2 2*,† 0* 1†
2-2-2-2-1 2*,† 0* 0†
2-2-2-2-2 57 24 14
2-2-2-3-2 0*,† 1* 1†
2-3-2-2-2 0† 0 1†
3-2-1-2-2 0* 2* 0
3-2-2-2-2 16 6 0
4-1-2-2-1 0‡ 1* 0
4-1-2-3-1 10§ 6 0§
4-2-1-2-2 3‡,§ 4‡ 2§
4-2-2-1-2 4‡,§ 1‡ 0§
4-2-2-2-2 52 41 19
4-2-2-3-1 4‡,§ 1‡ 2§
4-2-2-3-2 0‡,§ 1‡ 2§
4-3-2-2-1 0§,k 9k 3§
4-3-2-2-2 0‡,§ 1‡ 2§
4-3-2-3-1 27 10 4
4-3-2-3-2 1‡,§ 0‡ 0§
4-5-2-2-2 0‡ 1† 0
Total 196 120 58
a Superscript symbols denote alleles that were pooled on the basis
of at-risk allele 4 of the CA marker.
b ; (by the exact test).2x  12.50 P  .052
c ; (by the exact test).2x  13.04 P  .069
Table 6
Sequence Summary of MSX1 and TGFB3 Variants
Gene, Marker,
and Allele Mutationa
MSX1:
X1.1:
1 403 GrA, 5′ UTR
2 Published sequence
3 539 CrG, Ala34Gly
4 506 CrT, Ala23Val (two mothers of cases)
5 404 GrC, Gly12Arg in 5′ UTR open reading
frame (case from mother)
6 528 CrA, Ala31Glu (control father)
X1.3:
1 768 CrT, Gly110Gly
X2.1:
1 2081 GrA, Leu181Leu, and T insertion be-
tween positions 1968 and 1975
2 T insertion between positions 1968 and 1975
3 Published sequence
X2.4:
1 2438 CrT, 3′ UTR
TGFB3 5:
5′ UTR.1:
2  at 1083 to 1086 (AGAGGG repeat)
X2.1:
1 383 ArG, Lys128Arg
X5.1:
1 TrC, at position 24 relative to intron 4/
exon 5 junction
X7.1:
1 1116 CrG, Ala372Ala
a For MSX1 markers, the nucleotide numbers correspond to those
of Hewitt et al. (1991); for TGFB3 markers, the nucleotide numbers
are relative to the translation-initiation codon (Derynck et al. 1988;
ten Dijke et al. 1988; Lafyatis et al. 1990).
humans may result in a cleft palate along with other
craniofacial anomalies (Qiu et al. 1995).
MSX1 Mutation Screening and LD
LD was found between both CL/P and CPO and the
MSX1 X1.3 marker, a neutral polymorphism, when pa-
tient and control populations were compared. In addi-
tion, LD between CPO and the MSX1 CA marker exists.
The LD between MSX1 X1.3 and CL/P or CPO, ob-
served by the case-control–based analysis, was not con-
firmed by the nuclear-family–based analyses. There was
no evidence of LD between any of the other MSX1
markers and CL/P. However, significant LD between the
MSX1 CA and CPO was confirmed by the AFBAC
analysis.
Haplotype comparison of the CL/P or CPO probands
with the controls showed evidence of nearly significant
LD with the 4-2-2-2-2 and 4-3-2-2-1 haplotypes, sug-
gesting that they may carry a mutation involved in the
etiology of CL/P and CPO. The 4-2-2-2-2 haplotype rep-
resents the association of CA allele 4 and the common
alleles for the other markers, which correspond with the
published sequences. The 4-3-2-2-1 haplotype, which is
not found on any of the control chromosomes, contains
an amino acid substitution, Ala34Gly. This substitution
may affect a series of alanine residues in the N-terminal
region which may be important for normal function
(Mortlock et al. 1996; Zhang et al. 1996). Analysis of
the haplotype data for the CL/P and CPO patients did
not show significant LD with haplotypes of all five mark-
ers, either by case-control– or family-based analyses (ta-
bles 4 and 5). However, the same haplotypes—4-2-2-2-
2 and 4-3-2-2-1—were transmitted more frequently to
the affected probands.
The entire MSX1 coding region was screened in 69
CPO patients and 24 CL/P patients from Iowa. In ad-
dition, this region was screened, by means of the MSX1
X1.1, MSX1 X1.3, MSX1 X2.1, and MSX1 X2.4 prim-
ers, in a much larger number of CL/P patients during
the genotyping process. No obvious mutations were
identified that would alter the known function of MSX1,
including the function of either the homeodomain or a
potential phosphorylation site upstream of the homeo-
domain, by a cAMP-dependent phosphorylation protein
kinase. Therefore, it is unlikely that mutations in these
elements are common in CPO patients. However, a num-
ber of variants of unknown effect were identified, which
in the future may be shown to have an etiologic role by
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Table 7
TGFB3 Haplotypes for Markers 5′ UTR.1 and X5.1: TDT and AFBAC Analysis in CL/P Patients
Haplotype
TDT AFBAC
Transmitted Untransmitted x2 P Transmitted Untransmitted x2 P
1-1 17 6 90 79
1-2 2 9 2* 9*
2-1 4 7 4* 8*
2-2 0 0 7.02 .03 0 0 5.81 .008a
a LRT statistic.
a) altering the protein function or b) affecting splicing
through alterations in exonic splicing elements, which
have been described in other genes (Cooper and Mattox
1997). If these variants do not affect MSX1 function,
then it may be necessary to extend the mutation search
to enhancer regions shown to regulate MSX1 in mice
(MacKenzie et al. 1997).
It has been proposed that cleft palate in Msx1 knock-
out mice is due to insufficient palatal mesenchyme,
which, in turn, is due to the lack of dental development
(Ferguson 1994). This is supported by a higher fre-
quency of anodontia in cleft patients than in controls
(Ranta 1986). A family with partial anodontia and a
mutation in the MSX1 homeobox has been described
elsewhere (Vastardis et al. 1996). None of the family
members had a cleft lip or cleft palate. However, the
maxilla of the proband was described as being slightly
smaller, although within the normal range. It is possible
that the MSX1 mutation may also be affecting the mid-
face region, but not severely enough to result in a cleft
palate. Alternatively, the small maxilla may be a char-
acteristic of this family that is independent of the MSX1
mutation, since this is a relatively common trait in hu-
mans. This suggests that, for null MSX1 mutations to
be associated with palatal clefts, complete anodontia
may need to occur. We plan to correlate anodontia and
the MSX1 genotypes, in both cleft and control subjects.
TGFB3 Mutation Screening and LD
Despite the wealth of data from expression assays
(Fitzpatrick et al. 1990; Pelton et al. 1990), transgenic
knockout mice, (Kaartinen et al. 1995; Proetzel et al.
1995), and inactivation of TGFB3 by antisense oligonu-
cleotides and antibodies (Brunet et al. 1995), which in-
dicate that TGFB3 has a crucial role in secondary palate
development, there is no genetic evidence for this in the
Iowa population. This may suggest that the lack of pal-
ate fusion, especially that which is due to TGFB3 mu-
tations, is not a common cause of CPO in humans, in-
dicating that the developmental etiology of secondary
palate clefts may be different in humans than it is in
mice. However, it is possible that numerous mutations
have arisen on different backgrounds, in which case LD
would not be detected but linkage could exist.
A mutation screen of the Iowa CPO population was
performed under the hypothesis that, despite the lack of
evidence that TGFB3 plays a role at the population level,
the considerable biological evidence for the role of
TGFB3 in secondary palate development supports the
hypothesis that either a small number of individuals may
have a causal mutation in the coding region of the gene,
or heterogeneity may have prevented LD detection. Two
rare variants were identified in two CPO individuals.
The first of these rare variants, TGFB3 X7.1, is a neutral
mutation and was transmitted from the mother, who is
phenotypically normal, whereas the father, who does not
have the variant, has CPO, indicating that this variant
is not etiologic for CPO. The second rare variant, TGFB3
X2.1, results in a conservative amino acid change,
Lys128Arg, in the protein-precursor region. This X2.1
variant may be a rare, functionally neutral variant; how-
ever, it has not been identified in almost 700 control
chromosomes ( ), and this amino acid is con-P  .023
served in mammals (Denhez et al. 1990). The subject
who was heterozygous for this variant has a submucous
cleft palate. TGFB3 null mice have been described as
having a similar phenotype in situations in which fusion
has occurred (Proetzel et al. 1995). In this family, the
variant was maternally transmitted. Interestingly, the
mother and some of her relatives have scarring of the
lip, which apparently is due to spontaneous in utero
repair of a cleft lip (MIM 600625), which is a rare oc-
currence (Castilla and Martinez-Frias 1995).
The identification of only two coding variants in CPO
patients indicates that mutations of the protein are not
common in this population. Other potential sites for
mutations include the small fourth exon, the regulatory
regions in the promoter, and the 5′ and 3′ UTRs.
The LD between TGFB3 and CL/P was unexpected,
given the lack of a similar phenotype in the knockout
mouse and the lack of LD with CPO in humans. This
is supported by the recent report of LD with D14S61 in
nuclear families that have either CPO or CL/P (Maestri
et al. 1997). The lack of LD between CL/P and the
TGFB3 CA marker could occur if several mutations
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arose on different CA alleles, whereas, for the other two
TGFB3 markers, mutations always arose on the more
common alleles.
There was no evidence for a maternal effect, with
either CL/P or CPO, when the TGFB3 5′ UTR.1–X5.1
haplotype was used. A precedent for this exists in TGFB1
in mice (Letterio et al. 1994). It is unknown whether
TGFB3 can act similarly, but the presence of a cleft-
palate phenotype in null embryos from hemizygous
dams (Kaartinen et al. 1995; Proetzel et al. 1995) in-
dicates that TGFB3 may be different from TGFB1 in this
respect.
There was a suggestion of interaction between the
MSX1 and TGFB3 loci, in the etiology of CL/P. A com-
bination of alleles was observed in 7.6% of the CL/P
patients and in 1.0% of the controls. Therefore, this
combination may explain a significant proportion of CL/
P patients, in light of the hypothesized relative risks for
the etiologic genes.
The expression of TGFB3 has not been described dur-
ing primary palate formation, which also involves fu-
sion. It may be that TGFB3 is expressed in the epithelium
of the developing nasal and maxillary processes in the
area of future fusion. The absence of a cleft-lip pheno-
type in mice lacking TGFB3 may be due to strain dif-
ferences in susceptibility to cleft lip versus cleft palate.
The data for human CL/P and TGFB3 warrant screening
of CL/P patients for causal mutations in the gene. This
is also supported by an increased risk for CL/P and CPO
when smoking and/or alcohol exposure occur in con-
junction with certain TGFB3 genotypes (P.A. Romitti
and J.C. Murray, unpublished data), which recently has
been reported (Maestri et al. 1997).
Strict interpretation of statistical significance would
indicate that the LD data presented here could be due
to chance. Yet, the data must be interpreted in light of
other biological data supporting a higher prior proba-
bility of an etiologic role. Final interpretation will be
facilitated by replication in additional populations.
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